Biomodulina T- CIMAvax-EGF-Advanced Non-Small Cell Lung Cancer-Adults
- Conditions
- on-small cell lung cancerCarcinoma, Non-Small-Cell LungCarcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsLung DiseasesRespiratory Tract Diseases
- Registration Number
- RPCEC00000358
- Lead Sponsor
- Center of Molecular Immunology (CIM)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1. Patients of any sex and age over or equal to 18 years old.
2. Patients diagnosed with cyto/histological carcinoma of non-small lung cells in all stages IIIb and IV
3. Patients who have signed informed consent for research
4. Patients with clinical status criteria (ECOG) from 0 to 2
1. Patients of childbearing potential who are not using an appropriate method of contraception (intrauterine devices, hormonal contraceptives, barrier methods or tubal ligation). In case of male sex (vasectomy, condom use) for the duration of treatment.
2. Pregnant, lactating or post-breastfeeding patients.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.